RESUMEN
Intracellular concentrations of prednimustine (PM), chlorambucil (CLB), phenylacetic acid mustard (PAAM) and prednisolone (P) were measured in different experimental tumor cell lines that had been incubated with either PM or CLB + P. For intracellular analytical determination, we modified a high-pressure liquid chromatographic method for the detection of these substances in plasma. Intact PM could be detected in the intracellular compartment of the incubated tumor cells. PM-incubated cells from PM-injected rats exhibited a higher intracellular concentration-time integral (PAAM) and longer concentration-time profiles for drugs with alkylating capacity than did cells exposed to the CLB + P mixture or to CLB. PAAM was not detectable after incubation of cells with PM, whereas in CLB-incubated cells the AUC of PAAM exceeded that of the parent drug CLB. Our in vitro results therefore favour the concept of a facilitated intracellular uptake and an increased antiproliferative effect for PM versus CLB and CLB + P.
Asunto(s)
Clorambucilo/farmacocinética , Prednimustina/farmacocinética , Prednisolona/farmacocinética , Animales , Carcinoma/metabolismo , Clorambucilo/análisis , Cromatografía Líquida de Alta Presión/instrumentación , Cromatografía Líquida de Alta Presión/métodos , Neoplasias del Colon/metabolismo , Neoplasias Mamarias Experimentales/metabolismo , Melanoma Experimental/metabolismo , Compuestos de Mostaza Nitrogenada/análisis , Compuestos de Mostaza Nitrogenada/farmacocinética , Leucemia-Linfoma Linfoblástico de Células Precursoras/metabolismo , Prednimustina/análisis , Prednisolona/análisis , Ratas , Factores de Tiempo , Células Tumorales Cultivadas/metabolismoRESUMEN
The pharmacokinetic characteristics of prednisolone and of chlorambucil and its beta-oxidized metabolite, phenylacetic mustard (PAM) were studied in plasma after the oral administration of 200 mg prednimustine (Sterecyt) and a regimen consisting of 20 mg prednisolone plus 20 mg chlorambucil, respectively. A total of 12 cancer patients completed this trial. The drugs were given in a cross-over study as single doses, and serial plasma samples were collected for 32 h. Chlorambucil and PAM were assayed by a gas chromatographic/mass spectrometry method and prednisolone, by radioimmunoassay. The median relative availability of the prednisolone and chlorambucil moiety in prednimustine was 19% and 16%, respectively. Prednisolone, as well as chlorambucil and PAM, appeared later and at a significantly lower concentration in plasma after treatment with prednimustine as compared with the mixture of chlorambucil and prednisolone. We also found that the elimination phase of chlorambucil and PAM in plasma is prolonged after the administration of prednimustine as compared with chlorambucil per se. In contrast, the elimination of the prednisolone moiety of prednimustine and that following the administration of a plain prednisolone tablet did not seem to differ. The modified plasma profile of the alkylating components following prednimustine administration may be important for the clinical efficacy of prednimustine.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/farmacocinética , Neoplasias/sangre , Prednimustina/farmacocinética , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/sangre , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Disponibilidad Biológica , Clorambucilo/administración & dosificación , Clorambucilo/sangre , Clorambucilo/farmacocinética , Femenino , Cromatografía de Gases y Espectrometría de Masas , Humanos , Masculino , Persona de Mediana Edad , Neoplasias/tratamiento farmacológico , Prednimustina/administración & dosificación , Prednimustina/sangre , Prednisolona/administración & dosificación , Prednisolona/sangre , Prednisolona/farmacocinética , Radioinmunoensayo , Factores de TiempoRESUMEN
The pharmacokinetics of chlorambucil, phenylacetic acid mustard (the beta-oxidation product of chlorambucil), and prednisolone were investigated in a cross-over study after oral administration of chlorambucil (30 mg) + prednisolone (50 mg) versus prednimustine (300 mg), the ester of chlorambucil and prednisolone. Intact prednimustine could not be detected in plasma at any time. After administration of prednimustine, the plasma concentration-time curves of chlorambucil, phenylacetic acid mustard, and prednisolone showed a retarded profile compared to the administration of the single components. The mean bioavailability was 14% for chlorambucil, 21% for phenylacetic acid mustard, and 22% for prednisolone, when given as prednimustine, compared to the administration of free compounds in stoichiometrically equivalent doses. When given in the oral dosages mentioned above, the average dose-intensity was 62% for chlorambucil, 95% for phenylacetic acid mustard, and 72% for prednisolone, indicating sufficient therapeutic concentrations of the detectable agents.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/farmacocinética , Neoplasias de la Mama/tratamiento farmacológico , Clorambucilo/farmacocinética , Linfoma no Hodgkin/tratamiento farmacológico , Prednimustina/farmacocinética , Prednisolona/farmacocinética , Administración Oral , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/sangre , Clorambucilo/administración & dosificación , Clorambucilo/uso terapéutico , Femenino , Humanos , Linfoma no Hodgkin/sangre , Masculino , Tasa de Depuración Metabólica , Prednimustina/administración & dosificación , Prednimustina/uso terapéutico , Prednisolona/administración & dosificación , Factores de TiempoAsunto(s)
Clorambucilo/farmacocinética , Prednimustina/farmacología , Prednimustina/farmacocinética , Prednisolona/farmacocinética , Animales , Neoplasias de la Mama/metabolismo , División Celular/efectos de los fármacos , Línea Celular , Línea Celular Tumoral , Clorambucilo/farmacología , Cricetinae , Femenino , Humanos , Leucemia Linfoide/sangre , Linfocitos/efectos de los fármacos , Neoplasias Mamarias Experimentales/tratamiento farmacológico , Prednisolona/farmacología , RatasRESUMEN
Following the oral administration of either chlorambucil/prednisolone or prednimustine to patients, the plasma levels of free chlorambucil and phenylacetic acid mustard, the beta-oxidation product of chlorambucil, were measured using a new high-performance liquid chromatographic (HPLC) assay. This assay permitted the simultaneous detection of the analyzed compounds with a lower limit of detection of 30 ng/ml. The pharmacokinetics of chlorambucil and phenylacetic acid mustard were found to be entirely different when prednimustine was administered as opposed to its components chlorambucil and prednisolone together. After the ingestion of the conjugate, the plasma concentration-time curves of chlorambucil and phenylacetic acid mustard showed a "delayed" pattern compared with those obtained after the administration of the components. The mean area under the concentration-time curves (AUCs) of prednimustine-derived chlorambucil and phenylacetic acid mustard were 25% and 40%, respectively, of the areas obtained after a stoichiometrically equivalent dose of chlorambucil. Free plasma prednimustine could not be detected at any time. This different pharmacokinetic behavior might offer an explanation for the superior therapeutic effects of prednimustine demonstrated by clinical studies.